Health Condition 1: L438- Other lichen planus
Conditions
Interventions
Intervention1: Topical triamcinolone acetonide 0.1% oral paste for local applicarion thrice a day and oral apremilast 30 mg BD: Patients fulfilling the inclusion criteria will be included in the study
Sponsors
All India Institute of Medical Sciences, Jodhpur
Eligibility
Inclusion criteria
Inclusion criteria: a) Patients with clinical diagnoses of oral lichen planus or biopsy proven oral lichen planus. b) Age more than 16 years c) Treatment wash off period of 2 weeks for topical drugs and 4 weeks for immunosuppressive drugs.
Exclusion criteria
Exclusion criteria: a) Pregnant and lactating women b) Hypersensitivity to oral apremilast c) Known case of renal and hepatic impairment d) Known case of psychiatric disease e) Patients with extensive cutaneous involvement secondary to lichen planus. f) Patients with dental restoration in situ
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in clinical severity score (CSS)Timepoint: At 3 weeks, 6 weeks, 9 weeks and 12 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in pain on visual analog scaleTimepoint: At 3 weeks, 6 weeks, 9 weeks and 12 weeks.;Change in patientâ??s quality of life.Timepoint: At 3 weeks, 6 weeks, 9 weeks and 12 weeks.;Change in serum interleukin 6 & 8 (IL-6,IL-8)Timepoint: Baseline, at the end of treatment and in cases of relapse;Patient satisfaction with treatment using percentage gradingTimepoint: At 3 weeks, 6 weeks, 9 weeks and 12 weeks.;Side effects of drugTimepoint: At 3 weeks, 6 weeks, 9 weeks and 12 weeks. | — |
Countries
India
Contacts
Public ContactDr Anupama Bains
All India Institute of Medical Sciences, Jodhpur
Outcome results
None listed